Stemtech Corporation and Seacret Direct / Viago Execute Merger Agreement
Stemtech (OTCQB:STEK) has signed a merger agreement with Seacret Direct / VIÁGO through the issuance of 13 million preferred shares valued at $2.50 per share. The merger is expected to double Stemtech's revenue and create a vertically integrated company focused on health, longevity, and lifestyle solutions.
The transaction completion remains subject to conditions, including Seacret Direct / VIÁGO's audit, consents, and authorizations. The merged entity anticipates doubled revenue forecast for 2025 with planned cost synergies, aiming to deliver positive bottom-line results through optimization and existing growth trajectories.
Stemtech (OTCQB:STEK) ha firmato un accordo di fusione con Seacret Direct / VIÁGO attraverso l'emissione di 13 milioni di azioni privilegiate valutate a $2,50 per azione. Si prevede che la fusione raddoppi il fatturato di Stemtech e crei un'azienda verticalmente integrata focalizzata su soluzioni per la salute, longevità e stili di vita.
Il completamento della transazione è soggetto a condizioni, inclusi l'audit di Seacret Direct / VIÁGO, consensi e autorizzazioni. L'entità fusa prevede di raddoppiare le previsioni di fatturato per il 2025 con sinergie di costo pianificate, mirando a generare risultati positivi attraverso l'ottimizzazione e i percorsi di crescita esistenti.
Stemtech (OTCQB:STEK) ha firmado un acuerdo de fusión con Seacret Direct / VIÁGO mediante la emisión de 13 millones de acciones preferentes valoradas en $2.50 por acción. Se espera que la fusión duplicará los ingresos de Stemtech y creará una empresa verticalmente integrada enfocada en soluciones de salud, longevidad y estilo de vida.
La finalización de la transacción está sujeta a condiciones, incluyendo la auditoría de Seacret Direct / VIÁGO, consentimientos y autorizaciones. La entidad fusionada anticipa duplicar las previsiones de ingresos para 2025 con sinergias de costos planificadas, con el objetivo de ofrecer resultados positivos en la línea de fondo a través de la optimización y las trayectorias de crecimiento existentes.
Stemtech (OTCQB:STEK)는 Seacret Direct / VIÁGO와 1,300만 주의 우선주를 주당 $2.50로 발행하는 합병 계약을 체결했습니다. 이 합병은 Stemtech의 수익을 두 배로 늘릴 것으로 예상됩니다 하며, 건강, 장수 및 라이프스타일 솔루션에 중점을 둔 수직 통합 회사를 창출할 것입니다.
거래 완료는 Seacret Direct / VIÁGO의 감사, 동의 및 승인 등을 포함한 조건에 따라 달라집니다. 합병된 기업은 2025년을 위한 수익 예측이 두 배가 될 것으로 예상하며, 계획된 비용 시너지를 통해 최적화 및 기존 성장 궤적을 통해 긍정적인 최종 결과를 제공하는 것을 목표로 하고 있습니다.
Stemtech (OTCQB:STEK) a signé un accord de fusion avec Seacret Direct / VIÁGO par l'émission de 13 millions d'actions privilégiées évaluées à 2,50 $ par action. La fusion devrait doubler les revenus de Stemtech et créer une entreprise intégrée verticalement axée sur la santé, la longévité et les solutions de style de vie.
La réalisation de la transaction reste soumise à des conditions, y compris l'audit de Seacret Direct / VIÁGO, les consentements et les autorisations. L'entité fusionnée prévoit de doubler ses prévisions de revenus pour 2025 avec des synergies de coûts prévues, visant à fournir des résultats nets positifs grâce à l'optimisation et aux trajectoires de croissance existantes.
Stemtech (OTCQB:STEK) hat einen Fusionsvertrag mit Seacret Direct / VIÁGO unterzeichnet, in dem 13 Millionen Vorzugsaktien zum Preis von 2,50 $ pro Aktie ausgegeben werden. Es wird erwartet, dass die Fusion den Umsatz von Stemtech verdoppelt und ein vertikal integriertes Unternehmen schafft, das sich auf Gesundheits-, Langlebigkeits- und Lifestyle-Lösungen konzentriert.
Der Abschluss der Transaktion steht unter dem Vorbehalt bestimmter Bedingungen, einschließlich der Prüfung von Seacret Direct / VIÁGO, Zustimmungen und Genehmigungen. Die fusionierte Einheit erwartet, dass sich die Umsatzprognose für 2025 verdoppelt, mit geplanten Kostensynergien, mit dem Ziel, positive Ergebnisse durch Optimierung und bestehende Wachstumspfade zu erzielen.
- Merger expected to double company revenue
- Issuance of 13M preferred shares at $2.50 per share
- Anticipated cost synergies and positive bottom-line results
- Vertical integration strengthening market position
- Transaction completion subject to multiple conditions including audit
- Significant share issuance may lead to dilution
NAPLES, FL / ACCESSWIRE / December 4, 2024 / Stemtech Corporation (OTCQB:STEK) is pleased to announce the merger agreement with Seacret Direct / VIÁGO, progressing their plan to establish a global leadership position in defining the future of lifestyle, health and longevity. The transaction will be completed through the issuance of 13 million preferred shares with a stated value of
Stemtech Corporation ("Company") and Seacret have signed the agreement to complete the previously announced merger. The completion of this transaction remains subject conditions, including the audit of Seacret Direct / VIÁGO, consents and authorizations of the preferred stock and other customary conditions.
This transaction marks a pivotal milestone in the Company's evolution, expected to double the Stemtech revenue, in combination. The merger creates a vertically integrated powerhouse poised to lead and redefine health, longevity, and lifestyle for a public that demands smarter, more comprehensive solutions to improving quality of daily life. Highlighting a consolidated revenue forecast of double or more for 2025 with planned cost synergies, the merger is set to deliver positive bottom-line results through optimization and existing growth trajectories alone.
The Company will focus effort to accelerate its global growth already advancing through VIÁGO's aggressive brand campaign and streamlined membership offer to avail Stemtech's products to a growing savvy member base in addition to leading development of regionalized versioning of benefits to maximize customer value and appeal and referral virality.
Laying the foundation for and expanding the conglomerate portfolio, the Company will focus its attention on expanding its business to address the needs and desires of everyday people wanting to experience life better, longer.
Additional information about the transaction is provided in the Company's 8-K filing with the SEC.
Link: https://www.otcmarkets.com/filing/html?id=18022046&guid=4rY-keIcGgzLh3h
ABOUT VIAGO
VIÁGO is a lifestyle membership company entirely focused on amplifying the quality of life for everyone, with expertly curated vacation experiences, every-day wholesale travel, dining, theme park, concert and entertainment benefits, telemedicine and healthcare benefits, a member marketplace with world-class skin care and nutrition products. All of this through a single, simple membership model called CLUB VIÁGO, providing the highest standard of quality assurance and value for members every day, everywhere. VIÁGO is expanding rapidly while increasing benefits and localizing its offering to become a brand synonymous with living LIFE AMPLIFIED.
ABOUT STEMTECH
Stemtech Corporation, a leading stemceutical™ company was founded on April 18, 2018, after acquiring the operations from its predecessor Stemtech International, Inc., which was established in 2005. From 2010 through 2015, Stemtech International, Inc., was recognized four separate times on the Inc. 5000 Fastest-Growing Companies list. In August 2021, Stemtech became a publicly traded company "STEK". Stemtech is well positioned as the pioneer in stem cell nutrition, oral and skin care products, to increase sales in the wellness industry.
FORWARD-LOOKING STATEMENTS
This announcement contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as "believes," "will," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects," "forecast" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our annual report on Form 10-K filed on July 16, 2024 and our most recent 10-Q Report filed on November 19, 2024. We undertake no duty to update any forward-looking statement, or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Stemtech Corporation which are condoned by the Company must emanate from the Company itself and bear our name as its Source.
Investor Relations:
Gabriel Rodriguez
Email: erelationsgroup@gmail.com
Phone: +1 623-261-9046
Stemtech Corporation & Viago
Phone: +1 954-715-6000 ext 1040
Email: invrel@stemtech.com
SOURCE: Stemtech Corporation
View the original press release on accesswire.com
FAQ
What is the value of Stemtech's (STEK) merger with Seacret Direct?
How will the merger affect Stemtech's (STEK) revenue in 2025?
What conditions need to be met for Stemtech's (STEK) merger completion?
What is the strategic goal of Stemtech's (STEK) merger with Seacret Direct?
